Shots:
The company has received the US FDA’s clearance for the IND application to expand an ongoing P-I dose escalation and expansion trial to evaluate the safety and tolerability of NX-1607 in adults with advanced malignancies incl. a range of solid tumor indications
Patients are now being enrolled in the trial in the UK with clinical sites in the US being added later. The result from initial biomarker data from the P-I trial are expected in H1’22
NX-1607 is an orally bioavailable inhibitor of CBL-B for immuno-oncology indications incl. a range of solid tumor types. Additionally, the therapy showed single-agent anti-tumor activity in multiple tumor models
Ref: Nurix | Image: Nurix
